Cargando…
Patient- reported reasons for non-participation in a COVID-19 therapeutics clinical trial: Findings from a multi-center investigation
BACKGROUND: Early in the pandemic, there were no evidence-based treatments for SARS-CoV-2, creating an urgent need to identify effective therapeutics. However, public participation in medical research is low; trial enrollment in the US is typically 10–20%. Thus, the aim of this study was to identify...
Autores principales: | Dassum, Samira Reyes, Ferguson, Ryan, Woods, Patricia, Flynn, Maura, Visnaw, Karen, Holmberg, Erika, Schiller, Sara, Shannon, Colleen, Brophy, Mary, Monach, Paul, Leatherman, Sarah, Branch-Elliman, Westyn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827740/ https://www.ncbi.nlm.nih.gov/pubmed/36632925 http://dx.doi.org/10.1016/j.cct.2023.107082 |
Ejemplares similares
-
1065. Patient-Reported Reasons for Non-Participation in Inpatient COVID-19 Clinical Research: Results from a Multi-Center VA Embedded Randomized Trial
por: Reyes Dassum, Samira, et al.
Publicado: (2022) -
Implementation of documented and written informed consent for clinical trials of communicable diseases: Lessons learned, barriers, solutions, future directions identified during the conduct of a COVID-19 clinical trial
por: Woods, Patricia, et al.
Publicado: (2021) -
517. Subcutaneous Sarilumab for the Treatment of Hospitalized patients with Moderate to Severe COVID19 Disease: A Pragmatic, Embedded, Multi-Center Randomized Clinical Trial
por: Branch-Elliman, Westyn, et al.
Publicado: (2021) -
Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial
por: Branch-Elliman, Westyn, et al.
Publicado: (2022) -
Reconsidering ‘minimal risk’ to expand the repertoire of trials with waiver of informed consent for research
por: Monach, Paul A, et al.
Publicado: (2021)